OBJECTIVES: The aim of this study was to identify an association between the quality and functional activity of bone marrow-derived progenitor cells (BMCs) used for cardiovascular regenerative therapies and contractile recovery in patients with acute myocardial infarction included in the placebo-controlled REPAIR-AMI (Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction) trial. BACKGROUND: Isolation procedures of autologous BMCs might affect cell functionality and therapeutic efficacy. METHODS:Quality of cell isolation was assessed by measuring the total number of isolated BMCs, CD34+ and CD133+ cells, their colony-forming unit (CFU) and invasion capacity, cell viability, and contamination of the final BMC preparation with thrombocytes and red blood cells (RBCs). RESULTS: The number of RBCs contaminating the final cell product significantly correlated with reduced recovery of left ventricular ejection fraction 4 months after BMC therapy (p = 0.007). Higher numbers of RBCs in the BMC preparation were associated with reduced BMC viability (r = -0.23, p = 0.001), CFU capacity (r = -0.16, p = 0.03), and invasion capacity (r = -0.27, p < 0.001). To assess a causal role for RBC contamination, we coincubated isolated BMCs with RBCs for 24 h in vitro. The addition of RBCs dose-dependently abrogated migratory capacity (p = 0.003) and reduced CFU capacity (p < 0.05) of isolated BMCs. Neovascularization capacity was significantly impaired after infusion of BMCs contaminated with RBCs, compared with BMCs alone (p < 0.05). Mechanistically, the addition of RBCs was associated with a profound reduction in mitochondrial membrane potential of BMCs. CONCLUSIONS: Contaminating RBCs affects the functionality of isolated BMCs and determines the extent of left ventricular ejection fraction recovery after intracoronary BMC infusion in patients with acute myocardial infarction. These results suggest a bioactivity response relationship very much like a dose-response relationship in drug trials. (Reinfusion of Enriched Progenitor cells and Infarct Remodeling in Acute Myocardial Infarction [REPAIR-AMI]; NCT00279175).
RCT Entities:
OBJECTIVES: The aim of this study was to identify an association between the quality and functional activity of bone marrow-derived progenitor cells (BMCs) used for cardiovascular regenerative therapies and contractile recovery in patients with acute myocardial infarction included in the placebo-controlled REPAIR-AMI (Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction) trial. BACKGROUND: Isolation procedures of autologous BMCs might affect cell functionality and therapeutic efficacy. METHODS: Quality of cell isolation was assessed by measuring the total number of isolated BMCs, CD34+ and CD133+ cells, their colony-forming unit (CFU) and invasion capacity, cell viability, and contamination of the final BMC preparation with thrombocytes and red blood cells (RBCs). RESULTS: The number of RBCs contaminating the final cell product significantly correlated with reduced recovery of left ventricular ejection fraction 4 months after BMC therapy (p = 0.007). Higher numbers of RBCs in the BMC preparation were associated with reduced BMC viability (r = -0.23, p = 0.001), CFU capacity (r = -0.16, p = 0.03), and invasion capacity (r = -0.27, p < 0.001). To assess a causal role for RBC contamination, we coincubated isolated BMCs with RBCs for 24 h in vitro. The addition of RBCs dose-dependently abrogated migratory capacity (p = 0.003) and reduced CFU capacity (p < 0.05) of isolated BMCs. Neovascularization capacity was significantly impaired after infusion of BMCs contaminated with RBCs, compared with BMCs alone (p < 0.05). Mechanistically, the addition of RBCs was associated with a profound reduction in mitochondrial membrane potential of BMCs. CONCLUSIONS: Contaminating RBCs affects the functionality of isolated BMCs and determines the extent of left ventricular ejection fraction recovery after intracoronary BMC infusion in patients with acute myocardial infarction. These results suggest a bioactivity response relationship very much like a dose-response relationship in drug trials. (Reinfusion of Enriched Progenitor cells and Infarct Remodeling in Acute Myocardial Infarction [REPAIR-AMI]; NCT00279175).
Authors: Mortimer Korf-Klingebiel; Marc R Reboll; Stefanie Klede; Torben Brod; Andreas Pich; Felix Polten; L Christian Napp; Johann Bauersachs; Arnold Ganser; Eva Brinkmann; Ines Reimann; Tibor Kempf; Hans W Niessen; Jacques Mizrahi; Hans-Joachim Schönfeld; Antonio Iglesias; Maria Bobadilla; Yong Wang; Kai C Wollert Journal: Nat Med Date: 2015-01-12 Impact factor: 53.440
Authors: Claudia Zierold; Marjorie A Carlson; Udo C Obodo; Elizabeth Wise; Victor A Piazza; Marshall W Meeks; Rachel W Vojvodic; Sarah Baraniuk; Timothy D Henry; Adrian P Gee; Stephen G Ellis; Lemuel A Moyé; Carl J Pepine; Christopher R Cogle; Doris A Taylor Journal: Am Heart J Date: 2011-12 Impact factor: 4.749
Authors: Robert D Simari; Carl J Pepine; Jay H Traverse; Timothy D Henry; Roberto Bolli; Daniel B Spoon; Ed Yeh; Joshua M Hare; Ivonne Hernandez Schulman; R David Anderson; Charles Lambert; Shelly L Sayre; Doris A Taylor; Ray F Ebert; Lemuel A Moyé Journal: Circ Res Date: 2014-05-09 Impact factor: 17.367